DOCSLIB.ORG

Minutes of the CHMP Meeting 22-25 March 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minutes of the CHMP Meeting 22-25 March 2021 17 May 2021 EMA/CHMP/258452/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Minutes for the meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction 8 1.1. Welcome and declarations of interest of members, alternates and experts ............ 8 1.2. Adoption of agenda ................................................................................................ 8 1.3. Adoption of the minutes ......................................................................................... 8 2. Oral Explanations 9 2.1. Pre-authorisation procedure oral explanations ....................................................... 9 2.1.1. satralizumab - Orphan - EMEA/H/C/004788 .................................................................. 9 2.1.2. evinacumab - EMEA/H/C/005449 ................................................................................. 9 2.1.3. pitolisant - EMEA/H/C/005117 ..................................................................................... 9 2.1.4. trastuzumab - EMEA/H/C/005066 ................................................................................ 9 2.1.5. trastuzumab - EMEA/H/C/005880 .............................................................................. 10 2.2. Re-examination procedure oral explanations ....................................................... 10 2.3. Post-authorisation procedure oral explanations ................................................... 10 2.4. Referral procedure oral explanations ................................................................... 10 3. Initial applications 10 3.1. Initial applications; Opinions ................................................................................ 10 3.1.1. Copiktra - duvelisib - Orphan - EMEA/H/C/005381 ....................................................... 10 3.1.2. Drovelis - estetrol / drospirenone - EMEA/H/C/005336 ................................................. 11 3.1.3. Efmody - hydrocortisone - Orphan - EMEA/H/C/005105 ................................................ 11 3.1.4. Lydisilka - estetrol / drospirenone - EMEA/H/C/005382 ................................................ 12 3.1.5. Ponvory - ponesimod - EMEA/H/C/005163 .................................................................. 12 3.1.6. COVID-19 Vaccine Janssen - COVID-19 vaccine (Ad26.COV2-S [recombinant]) - EMEA/H/C/005737 ................................................................................................... 13 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ...................................................................... 13 3.2.1. evinacumab - EMEA/H/C/005449 ............................................................................... 13 3.2.2. eflornithine / sulindac - Orphan - EMEA/H/C/005043 .................................................... 14 3.2.3. trastuzumab - EMEA/H/C/005880 .............................................................................. 14 3.2.4. setmelanotide - Orphan - EMEA/H/C/005089 .............................................................. 14 3.2.5. insulin human (rDNA) - EMEA/H/C/005331 ................................................................. 15 3.2.6. pitolisant - EMEA/H/C/005117 ................................................................................... 15 3.2.7. trastuzumab - EMEA/H/C/005066 .............................................................................. 15 3.2.8. relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267 .................................. 16 3.2.9. sildenafil - EMEA/H/C/005439 ................................................................................... 16 3.2.10. vericiguat - EMEA/H/C/005319 .................................................................................. 16 3.2.11. obeticholic acid - EMEA/H/C/005249 .......................................................................... 16 Committee for medicinal products for human use (CHMP) EMA/CHMP/258452/2021 Page 2/62 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ...................................................................... 17 3.3.1. fingolimod - EMEA/H/C/005661 ................................................................................. 17 3.3.2. finerenone - EMEA/H/C/005200 ................................................................................. 17 3.3.3. maralixibat - Orphan - EMEA/H/C/005551 .................................................................. 17 3.3.4. metformin hydrochloride / sitagliptin hydrochloride monohydrate - EMEA/H/C/005678 ..... 17 3.3.5. arimoclomol - Orphan - EMEA/H/C/005203 ................................................................. 18 3.3.6. adrenaline - EMEA/H/C/005584 ................................................................................. 18 3.3.7. lasmiditan - EMEA/H/C/005332 ................................................................................. 18 3.3.8. sitagliptin fumarate - EMEA/H/C/005741 .................................................................... 18 3.3.9. tepotinib - EMEA/H/C/005524 ................................................................................... 19 3.3.10. teriparatide - EMEA/H/C/005543 ............................................................................... 19 3.4. Update on on-going initial applications for Centralised procedure ........................ 19 3.4.1. idecabtagene vicleucel - Orphan - EMEA/H/C/004662 ................................................... 19 3.4.2. leuprorelin - EMEA/H/C/005034 ................................................................................. 19 3.4.3. dasatinib - EMEA/H/C/005446 ................................................................................... 20 3.4.4. dasatinib - EMEA/H/C/005317 ................................................................................... 20 3.4.5. istradefylline - EMEA/H/C/005308 .............................................................................. 20 3.4.6. teriparatide - EMEA/H/C/004932 ............................................................................... 20 3.4.7. lonafarnib - Orphan - EMEA/H/C/005271 .................................................................... 21 3.4.8. pegfilgrastim - EMEA/H/C/004780 ............................................................................. 21 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 ............................................................................................................. 21 3.6. Initial applications in the decision-making phase ................................................. 21 3.7. Withdrawals of initial marketing authorisation application .................................. 21 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 22 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion ................................................................................ 22 4.1.1. Buvidal - buprenorphine - EMEA/H/C/004651/X/0008/G ............................................... 22 4.1.2. Diacomit - stiripentol - EMEA/H/C/000664/X/0032 ....................................................... 22 4.1.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0012 ..................................................... 23 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues ....................................... 23 4.2.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0024/G...................................................... 23 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question ...................................................... 24 4.3.1.
Load more

Recommended publications
  • Ganirelix) May Prevent Ovarian Hyperstimulation Syndrome Caused by Ovarian Stimulation for In-Vitro Fertilization
    Human Reproduction vol.13 no.3 pp.573–575, 1998 CASE REPORT High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization D.de Jong1, N.S.Macklon1, B.M.J.L.Mannaerts2, releasing hormone (GnRH) agonists in order to prevent H.J.T.Coelingh Bennink2 and B.C.J.M.Fauser1,3 unpredictable changes in release of endogenous gonadotrophins. However, it has been reported that the continued administration 1Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Dijkzigt Academic Hospital and Erasmus University of GnRH agonists does not affect subsequent ovarian quiescence Medical School, Dr. Molewaterplein 40, 3015 GD, Rotterdam and (Wadaet al., 1992). This may be related to prolonged suppression 2Scientific Development Group, NV Organon, Oss, The Netherlands of pituitary function due to slow recovery from down-regulation 3To whom correspondence should be addressed (Donderwinkel et al., 1993). Some residual gonadotrophin release may remain during GnRH agonist suppression, whereas This case report describes the first attempt to treat pituitary release of LH and follicle-stimulating hormone (FSH) imminent ovarian hyperstimulation syndrome (OHSS) by may be virtually abolished with the sustained use of a high dose using a gonadotrophin-releasing hormone (GnRH) of GnRH antagonist. In this case report we describe an alternative antagonist. A 33 year old, normo-ovulatory woman under- method, using a high dose of a GnRH antagonist which may going in-vitro fertilization received daily subcutaneous decrease the risk of a severe OHSS. injections of 150 IU of recombinant follicle-stimulating hormone (recFSH) from cycle day 2, together with GnRH antagonist (ganirelix) 0.125 mg from cycle day 7 onwards.
    [Show full text]
  • The Pharmacoeconomic Burden of Insomnia
    The Pharmacoeconomic Burden of Insomnia: Current Treatment Challenges and an Update on Safe and Efficacious Options © 2020. All rights reserved. No part of this report may be reproduced or distributed without the expressed written permission of PTCE. Faculty Information Julie A. Dopheide, PharmD, BCPP, FASHP Douglas S. Burgoyne, PharmD, FAMCP Professor of Clinical Pharmacy, Adjunct Associate Professor Psychiatry and the Behavioral Sciences Department of Pharmacotherapy University of Southern California School University of Utah College of Pharmacy of Pharmacy and Keck School of Medicine Salt Lake City, Utah Los Angeles, California This activity is supported by an educational grant from Eisai. Educational Objectives After completion of this activity, participants will be able to: • Characterize the pathophysiology, epidemiology, and disease burden of insomnia including the impact on quality of life in vulnerable patient groups • Identify appropriate pharmacotherapy for insomnia based on guideline recommendations, drug efficacy and safety profiles, and patient factors • Examine the economic burden of insomnia and impact of available treatment options, including effects on vulnerable patient groups Insomnia Overview Julie Dopheide, PharmD, BCPP, FASHP Emily Morris, 16 years old Emily Morris, 16 years old 2020 National Sleep Foundation Poll Shows High Levels of Daytime Sleepiness and Negative Health Impact #1 Cause of Daytime Sleepiness: Insomnia Health Impacts of Feeling Sleepy Feeling Sleepy How Many Days Per Week? 5-7 days 28% 28% 2-4 days 44% 0-1 days 0 20 40 60 1-2 days 2-4 days 5-7 days Feeling Unwell Headache Irritability Sleep in America Poll 2020. National Sleep Foundation. Published March 2020. Accessed October 8, 2020.
    [Show full text]
  • Fertility Medications: Bravelle®, Cetrotide®, Clomid, Clomiphene, Follistim AQ®, Ganirelix®, Gonal-F®, Human Chorionic Gonadotropin, Leuprolide
    Drug Therapy Guidelines Fertility Medications: Bravelle®, Cetrotide®, Clomid, clomiphene, Follistim AQ®, Ganirelix®, Gonal-F®, human chorionic gonadotropin, leuprolide, Menopur®, Novarel®, Ovidrel®, Pregnyl®, Crinone®, Applicable* Endometrin®, First-Progesterone®, progesterone in oil Medical Benefit x Effective: 08/03/2021 Pharmacy- Formulary 1 x Next Review: 6/22 Pharmacy- Formulary 2 x Date of Origin: 7/00 Pharmacy- Formulary 3/Exclusive x Review Dates: 7/12/00, 5/8/01, 1/15/02, 5/6/03, 12/16/03, 6/8/04, Pharmacy- Formulary 4/AON x 12/16/05, 2/1/06, 10/15/06, 7/20/07, 11/5/07, 12/15/08, 12/09, 9/10, 1/11, 9/11, 9/12, 9/13, 9/14, 6/15, 6/16, 6/17, 6/18, 6/19, 9/19, 3/20, 6/20, 9/20, 3/21, 6/21 I. Medication Description Gonadotropin Releasing Hormone (GnRH) Agonists are indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. GnRH Antagonists are indicated for inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. Gonadotropins, FSH, or combination of FSH/LH are indicated for stimulation of ovarian follicular growth. Human chorionic gonadotropins (hCG) are indicated for inducing ovulation. Clomiphene is a selective-estrogen receptor-modulator (SERM) used for inducing ovulation. Therapeutic Class Agents GnRH Agonists leuprolide GnRH Antagonists Cetrotide®, Ganirelix® Gonadotropins Follitropin alfa: Gonal-F®, Gonal-F RFF® (non-preferred) Follitropin beta: Follistim AQ® (preferred) Menotropins: Menopur® Urofollitropins: Bravelle® hCG human chorionic gonadotropin, Novarel®, Ovidrel®, Pregnyl® Progestin Injection progesterone oil for injection Vaginal Progesterone Crinone, Endometrin, First-Progesterone Selective-estrogen receptor- Clomid*, Clomiphene* modulator (SERM) II.
    [Show full text]
  • Clinical Pharmacology of Daridorexant, a Novel Dual Orexin Receptor Antagonist
    Clinical pharmacology of daridorexant, a novel dual orexin receptor antagonist Inauguraldissertation zur Erlangung der Würde eines Dr. sc. med. Vorgelegt der Medizinischen Fakultät der Universität Basel Von Clemens Mühlan aus 4055 Basel, Schweiz Basel, 2021 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Medizinischen Fakultät auf Antrag von Prof. Dr. Stephan Krähenbühl Prof. Dr. Matthias Liechti Dr. Alexander Jetter Dr. Jasper Dingemanse Basel, 24. Februar 2021 Dekan Prof. Dr. Primo Leo Schär 2 of 118 TABLE OF CONTENTS LIST OF ABBREVIATIONS AND ACRONYMS ............................................................4 ACKNOWLEDGEMENTS .................................................................................................8 SUMMARY .........................................................................................................................9 1 BACKGROUND AND INTRODUCTION ................................................................15 1.1 Insomnia .......................................................................................................15 1.2 The orexin system as a therapeutic target .....................................................18 1.3 Review of orexin receptor antagonists .........................................................20 1.4 Selective vs dual orexin receptor antagonism ..............................................23 1.5 Orexin receptor antagonists available in clinical practice ............................24 1.6 Orexin receptor
    [Show full text]
  • Follicular and Endocrine Profiles Associated with Different Gnrh
    Reproductive BioMedicine Online (2012) 24, 153– 162 www.sciencedirect.com www.rbmonline.com ARTICLE Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial Juan Antonio Garcı´a-Velasco a, Sanja Kupesic b, Antonio Pellicer c, Claire Bourgain d, Carlos Simo´n e, Milan Mrazek f, Paul Devroey g, Joan-Carles Arce h,* a IVI Foundation, Reproductive Endocrinology, Madrid, Spain; b Texas Tech University Health Sciences Center, Department of Obstetrics and Gynecology, El Paso, TX, USA; c IVI Foundation, Reproductive Endocrinology, Valencia, Spain; d UZ Brussel, Department of Pathology, Brussels, Belgium; e IVI Foundation, Research Department, Valencia, Spain; f ISCARE IVF a.s., Lighthouse, Prague, Czech Republic; g UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium; h Reproductive Health, Global Clinical and Non-Clinical R & D, Ferring Pharmaceuticals, Copenhagen, Denmark * Corresponding author. E-mail address: [email protected] (J.-C. Arce). Dr Juan Garcı´a-Velasco did his training in obstetrics and gynaecology at Madrid Autonoma University, and then his reproductive endocrinology and infertility fellowship at Yale University, USA (1997–1998). He is now Director of IVI-Madrid and Associate Professor at Rey Juan Carlos University. He has published over 100 peer- reviewed articles. He is an ad-hoc reviewer for the main journals in the field and serves on the editorial board of Reproductive BioMedicine Online. His main research interests are endometriosis, ovarian hyperstimulation syndrome, low responders and human implantation. Abstract This trial assessed the impact of early initiation of gonadotrophin-releasing hormone (GnRH) antagonist on follicular and endocrine profiles compared with the fixed GnRH-antagonist protocol.
    [Show full text]
  • Ganirelix Acetate) Injection
    1 Antagonä (ganirelix acetate) Injection 2 FOR SUBCUTANEOUS USE ONLY 3 4 DESCRIPTION 5 Antagonä (ganirelix acetate) Injection is a synthetic decapeptide with high antagonistic 6 activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix 7 acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 8 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2- 9 naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl- 10 N9,N10-diethyl-D-homoarginyl-L-leucyl-N9,N10-diethyl-L-homoarginyl-L-prolyl-D- 11 alanylamide acetate. The molecular weight for ganirelix acetate is 1570.4 as an anhydrous 12 free base. The structural formula is as follows: 13 Ganirelix acetate 14 15 16 17 18 19 + x C2H4O2 + y H2O 20 21 Antagonä is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for 22 SUBCUTANEOUS administration only. Each sterile, pre-filled syringe contains 250 Ganirelix PI 1 23 mg/0.5 mL of ganirelix acetate, 0.1 mg glacial acetic acid, 23.5 mg mannitol, and water for 24 injection adjusted to pH 5.0 with acetic acid, NF and/or sodium hydroxide, NF. 25 CLINICAL PHARMACOLOGY 26 The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing 27 hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in 28 the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be 29 detected as transient rises in serum LH.
    [Show full text]
  • Antagonists in Poor-Responder Patients
    FERTILITY AND STERILITY௡ VOL. 80, SUPPL. 1, JULY 2003 Copyright ©2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Antagonists in poor-responder patients Alan B. Copperman, M.D. Mount Sinai School of Medicine, New York, New York Objective: To review treatment options for poor-responding patients who are undergoing infertility treatment. Design: Review article and case studies. Results: A comprehensive determination of potential ovarian response for the poor-responding patient is important in the individualization of treatment options for these patients. Treatment options include both the microdose flare leuprolide acetate and GnRH antagonist stimulation protocols. For GnRH antagonist stimu- lation protocols, individualization of treatment includes use of oral contraceptive pretreatment and alterations in duration of gonadotropin stimulation and start day of antagonist administration. Conclusions: For poor-responding patients, the benefits of using GnRH antagonists for the suppression of premature LH surges plus the determination that stimulation protocols that include GnRH antagonists are at least as good as the microdose flare and provide better cycle outcomes than the long luteal leuprolide acetate down-regulation protocols have the potential to bring changes to the existing protocols for ovarian stimulation. (Fertil Steril௡ 2003;80(Suppl 1):S16–24. ©2003 by American Society for Reproductive Medicine.) Key Words: Ganirelix, GnRH antagonist, poor ovarian response, treatment options Individualization of stimulation regimens, ment modalities in COH, it is also important to prospective analysis of ovarian reserve, and have a clear understanding of inclusion criteria setting defined goals regarding ovarian re- for the poor-responder patient.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Ganirelix Acetate Injection, Solution Organon USA Inc
    GANIRELIX ACETATE- ganirelix acetate injection, solution Organon USA Inc. ---------- Ganirelix Acetate Injection FOR SUBCUTANEOUS USE ONLY DESCRIPTION Ganirelix Acetate Injection is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH). Ganirelix Acetate is derived from native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, 8, and 10 to form the following molecular formula of the peptide: N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D- alanyl-L-seryl-L-tyrosyl-N9,N10-diethyl-D-homoarginyl-L-leucyl-N9,N10-diethyl-L-homoarginyl-L- prolyl-D-alanylamide acetate. The molecular weight for Ganirelix Acetate is 1570.4 as an anhydrous free base. The structural formula is as follows: Ganirelix Acetate Ganirelix Acetate Injection is supplied as a colorless, sterile, ready-to-use, aqueous solution intended for SUBCUTANEOUS administration only. Each single dose, sterile, prefilled syringe contains 250 mcg/0.5 mL of Ganirelix Acetate, 0.1 mg glacial acetic acid, 23.5 mg mannitol, and water for injection adjusted to pH 5.0 with acetic acid, NF and/or sodium hydroxide, NF. CLINICAL PHARMACOLOGY The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization.
    [Show full text]
  • In Vitro Fertilization Basics
    IN VITRO FERTILIZATION BASICS www.massgeneral.org/fertility 1 Revised 03/2019 Table of Contents Page Pre-treatment Recommendations 3 Medication Overview 4 - 10 Cycle Monitoring 11 Cycle Cancellation 12 Pre-egg Retrieval Instructions 12 Pre-op Surgery Instructions 13 Day of Egg Retrieval Instructions 14-15 Day of Retrieval Male Instructions 15 Instructions After Egg Retrieval 16 Insemination and Fertilization 16 Day of Embryo Transfer 17 Guidelines for Number of Embryos for Transfer 18 Instructions After Egg Retrieval 19 Pregnancy 19 Important Telephone and Contact Information 20 2 Revised 03/2019 Pre-Treatment Recommendations Many factors that influence your fertility are not within your control but there are some things that you can do to optimize your chance for success as you prepare for treatment. Please follow these lifestyle recommendations. • Take a multivitamin supplement containing at least 400 mcg of folic acid each day. • Eat a well-balanced diet. • Do not smoke, use nicotine products, drink alcohol, or use recreational drugs. • Limit your caffeine intake to one 12-ounce beverage each day. • Do not take aspirin or ibuprofen (Motrin or Advil). Take Tylenol for pain. • Avoid all herbal products and supplements, including soy, unless advised by your primary fertility specialist. • When you receive your medications for treatment, open the box and verify that all the medications are correct. Please call your nurse on the first or second day of your period to start your IVF cycle. She will discuss your treatment plan, including your medication order and give you specific instructions regarding your medication schedule. We do all our teaching online through EngagedMD.
    [Show full text]
  • Impact of Mild Ovarian Stimulation on Implantation
    3/4/2009 Impact of mild ovarian stimulation on implantation Juan A GarciaGarcia--VelascoVelasco IVIIVI--MadridMadrid Rey Juan Carlos University, Madrid, Spain Window of Implantation hCGLH+0 injection STIMULATEDNATURAL CYCLES CYCLES 14 15 16 17 18 19 20 21 hCG+2LH+2 hCG+7LH+7 Bergh P, Navot D. Fertil Steril 1992; 58: 537‐42 Implantation Hydrosalpinx/ Endom. cavity COH Trombophilias Embryo Endometrium (morphologic, genetic) (morphologic, genetic) Embryo transfer 1 3/4/2009 Factors involved Controlled Ovarian Hyperstimulation High levels of estradiol ENDOMETRIUM ? EMBRYO ? LOW IMPLANTATION RATES IN HIGH RESPONDER PATIENTS • Clinical studies showing low IR in high responder patients (Pellicer et al. Hum Reprod 1989; Simón C et al. Hum Reprod 1995; Pellicer at al. Fertil Steril 1996; Valbuena et al, Hum Reprod 1999) • Endometrial receppytivity but not embryo qqyuality is affected (Simón C et al. Hum Reprod 1995; Valbuena et al, Hum Reprod 1999) • Evidence of altered endocrine milieu in the periimplantation period (Pellicer A et al. Fertil Steril 1996) • Increased IR when E2 levels were lower in subsequent cycles (Simón C et al. Fertil Steril 1998; 70:234-9) • Extremely high E2 levels are embryotoxic for the embryo (Valbuena et al. Fertil Steril 2001) 2 3/4/2009 • Receptive endometrium features » Morphological markers » Biochemical markers » Gene expression pattern 3 3/4/2009 GarciaGarcia--VelascoVelasco et al, 1999 The evolution of technology The evolution of technology 1983 2008 3995 US$ 300 US$ 4 3/4/2009 The evolution of technology MICROARRAY TECHNOLOGY Reproduction 160 • Microarray analysis, first described in 1995 (Schena, Science) 4.567 140 • Based120 on nucleic acid complementarity.
    [Show full text]
  • ACNP 59Th Annual Meeting: Poster Session I
    www.nature.com/npp ABSTRACTS COLLECTION ACNP 59th Annual Meeting: Poster Session I Neuropsychopharmacology (2020) 45:68–169; https://doi.org/10.1038/s41386-020-00890-7 Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Presenting author disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting. M1. Juvenile Social Isolation of Rats Induces Lost of Jessica Jessica Deslauriers*, Jose Figueroa, Cindy Napan, Corticotropin Releasing Factor-Receptor 1 Antagonist Effect in Yanilka Soto-Muniz, Victoria Risbrough the Nucleus Accumbens Université Laval, Québec, Canada Katia Gysling*, Juan Zegers, Javier Novoa, Hector Yarur Background: Post-traumatic stress disorder (PTSD) is a common Pontificia Universidad Catolica de Chile, Santiago, Chile psychiatric condition that is defined by its paradigmatic symptoms including but not limited to anxiety, avoidance, and increased arousal Background: Social isolation is a model of chronic stress widely by environmental cues due to a severely traumatic event. Recent used to study early life adversity. It is well known that early life studies show that this condition is correlated with both peripheral 1234567890();,: adversity may lead to the development of psychiatric disorders in and central immune dysfunction, but the relationship between adulthood. Juvenile rats exposed to social isolation showed inflammation and PTSD remains unclear. In a mouse model of PTSD, increased anxiety-like behavior and significant changes in Nucleus we found increased plasma levels of the pro-inflammatory cytokine Accumbens (Nac) dopamine (DA) activity in adulthood (Lukkes interleukin-1β (IL-1β) after exposure to trauma. A major component in et al.
    [Show full text]